Canary expands ETF offerings with Injective staking exposure
Canary Capital files for Injective (INJ) staking ETF with SEC
Canary Capital has filed with the U.S. Securities and Exchange Commission to launch a new Injective (INJ) staking ETF, marking a significant move in broadening institutional access to altcoins.
The proposed fund would stake a portion of its INJ holdings on the native Injective network, offering passive income through on-chain rewards — estimated at up to 11.5%, depending on validator selection, reports Cryptopolitan.
This makes it one of the first ETFs to tap into staking yields from smaller blockchain ecosystems, highlighting a shift in investor appetite beyond blue-chip assets like Bitcoin and Ethereum. Injective welcomed the ETF application as a vote of confidence in its technology, noting the inclusion of staking adds real yield potential to the fund structure.
Institutional spotlight lifts Injective price and ecosystem outlook
News of the ETF filing catalyzed a 25% weekly gain for INJ, pushing its price to $13.49. While Injective has long branded itself as a high-performance DeFi-focused chain, it has lagged behind in terms of adoption, with only $37 million in total value locked (TVL) as of July. Still, July activity has spiked, with daily active addresses reaching 71,000, following months of stagnation. The network’s validator set — comprising 51 nodes — includes key players like Kiln (with $68M staked) and Deutsche Telekom, adding legitimacy to its staking infrastructure. If approved, the ETF could bring mainstream awareness and liquidity to a network that’s often overlooked by larger funds.
Growing ETF race now includes overlooked altcoins
Canary Capital’s initiative points to a broader shift in ETF strategy, as institutions explore staking-based returns and altcoin exposure. The firm is reportedly eyeing additional products for LTC, TRX, SUI, and HBAR, building on industry attention surrounding pending ETFs for XRP and SOL. The move could further legitimize smaller-cap assets, especially those with strong staking economics and validator networks. If the Injective ETF gains approval, it may pave the way for other yield-bearing altcoin ETFs, expanding the competitive landscape of digital asset funds and diversifying institutional portfolios beyond Bitcoin and Ethereum.
Recently we wrote that despite a sharp price dip below $116,000, institutional investors continued to increase exposure to Bitcoin, adding nearly 11,000 BTC to spot Bitcoin ETFs in just two days.
